Join
Live feed
·
PRReleasevia Quantisnow
Elicio Therapeutics Inc. logo

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ELTX· Elicio Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELTX (Elicio Therapeutics Inc.) and more on Quantisnow.